Researchers at The Ohio State University have discovered new drugs for augmenting perfusion pressure administered during cardiopulmonary resuscitation and other shock states. Approximately 450,000 people yearly suffer a cardiac arrest outside the hospital with less than 10% of these patients discharged from the hospital alive, and of these, approximately 60% suffer some form of permanent neurological injury. While epinephrine is used during CPR to enhance perfusion, new drugs are needed to optimize hemodynamics and minimize toxicity. The new drugs discovered at Ohio State include phenylethanolamines and imidazolines, and fluorinated derivatives thereof, which act on adrenergic receptors in patients. These compounds effectively enhance neurological outcome and survival, and decrease ventricular dysrhythmias in patients suffering cardiac arrest and other shock states.
This lifesaving drug can be administered after experiencing a traumatic shock like cardiac arrest or other shock states.
- More effective at optimizing hemodynamics and minimizing toxicity compared to epinephrine which is currently used.
- Makes use of adrenergic receptors which has been shown to be more effective than CPR alone.